Curve Biosciences develops Whole-Body Intelligence models using a proprietary Whole-Body Atlas of over 400,000 curated tissue samples. These models power Whole-Body Blood Tests designed to monitor organ health in chronic disease patients. This approach aims to provide more accurate monitoring than standard methods for managing long-term health conditions.
Funding
$17.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early detection of liver cancer is crucial for effective treatment, but current screening methods often lack the sensitivity and specificity needed for timely diagnosis. This can lead to delayed treatment and poorer patient outcomes.
Solution
This startup is developing liver cancer diagnostics using a proprietary LAMB method. This method combines data structuring and mining techniques with high-resolution assays to create precise diagnostic tests. The technology aims to improve disease prevention and screening for liver cancer by providing healthcare professionals with more accurate and timely diagnostic information. This enables earlier intervention and potentially improves patient outcomes.
Target Audience
The primary target audience includes healthcare professionals involved in liver cancer screening and diagnosis, such as oncologists, hepatologists, and radiologists.
Features
- Patent-protected LAMB method for liver cancer diagnostics
- Data structuring and mining techniques to enhance diagnostic accuracy
- High-resolution assays for precise detection of liver cancer biomarkers